EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds

Jie Mi, Xueqiong Wu, Jianqin Liang

Frontiers in Microbiology · 20.06.2024 · 15

DOI: 10.3389/fmicb.2024.1380848 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 20.06.2024. Verfasst von Jie Mi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculos…. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) is a chronic bacterial disease, as well as a complex immune disease. The occurrence, development, and prognosis of TB are not only related to the pathogenicity of Mycobacterium tuberculosis ( Mtb ), but also related to the patient’s own immune state. The research and development of immunotherapy drugs can effectively regulate the body’s anti-TB immune responses, inhibit or eliminate Mtb , alleviate pathological damage, and facilitate rehabilitation. This paper reviews the research progress of immunotherapeutic compounds for TB, including immunoregulatory compounds and repurposing drugs, and points out the existing problems and future research directions, which lays the foundation for studying new agents for host-directed therapies of TB.

Schlagwörter

Stichwörter der Autor:innen

compoundshostdirected therapyimmunomodulatorsimmunotherapytuberculosis

Autor:innen und Institutionen

  • Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China.
  • Department of Tuberculosis, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing, China.

Zitieren

APA

Mi, J., Wu, X., & Liang, J. (2024). The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds. Frontiers in Microbiology, 15. https://doi.org/10.3389/fmicb.2024.1380848

Vancouver

Mi J, Wu X, Liang J. The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds. Frontiers in Microbiology. 2024;15. doi:10.3389/fmicb.2024.1380848

BibTeX
@article{Mi2024,
  author = {Mi, Jie and Wu, Xueqiong and Liang, Jianqin},
  title = {The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds},
  journal = {Frontiers in Microbiology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fmicb.2024.1380848}
}
Kostenlos starten →